With a number of drug price systems in operation within the positive list system, the government is conducting six studies on drug price policies related to insurance benefit entry permits and follow-up management, drawing attention to how the results will be reflected next year. According to the Ministry of Health and Welfare, this year, the insurance authorities are conducting six studies on the ▲ actual transaction price system, ▲ low-priced purchase incentive system, ▲ PVA improvement, ▲ RSA performance evaluation and future improvement, ▲ drug price adjustment system, and ▲ plasma raw materials.

These studies are expected to be an important basis for the reorganization or improvement of the g